Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03170206 · ClinicalTrials.gov registry record · Phase 1
Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT03170206 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 34 participants.
The verdict
NCT03170206, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This trial is being conducted as a possible treatment for lung cancer with a specific change in the KRAS gene. The drugs involved in this study are: * Palbociclib * Binimetinib
Interventions
- DRUG Palbociclib
- DRUG Binimetinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2017-05-31 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03170206
The ClinicalTrials.gov registry entry for NCT03170206 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Palbociclib is the first listed.
NCT03170206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03170206 about?
NCT03170206 is a clinical study titled "Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer". This trial is being conducted as a possible treatment for lung cancer with a specific change in the KRAS gene. The drugs involved in this study are: * Palbociclib * Binimetinib
What is the current status of trial NCT03170206?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2017-05-31. Estimated completion is 2025-12-31.
What interventions are being tested in trial NCT03170206?
The interventions under investigation include: Palbociclib (DRUG), Binimetinib (DRUG).
Who is sponsoring clinical trial NCT03170206?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.